BG104062A - Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor - Google Patents

Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor

Info

Publication number
BG104062A
BG104062A BG104062A BG10406200A BG104062A BG 104062 A BG104062 A BG 104062A BG 104062 A BG104062 A BG 104062A BG 10406200 A BG10406200 A BG 10406200A BG 104062 A BG104062 A BG 104062A
Authority
BG
Bulgaria
Prior art keywords
stimulant
alpha
treatment
insulin secretion
diabetes
Prior art date
Application number
BG104062A
Other languages
Bulgarian (bg)
English (en)
Inventor
Robin Buckingham
Stephen Smith
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of BG104062A publication Critical patent/BG104062A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
BG104062A 1997-07-18 2000-01-06 Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor BG104062A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002112 WO1999003478A1 (fr) 1997-07-18 1998-07-16 Traitement du diabete avec du thiazolidinedione, un secretagogue d'insuline et un inhibiteur d'alpha glucosidase

Publications (1)

Publication Number Publication Date
BG104062A true BG104062A (en) 2000-11-30

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
BG104062A BG104062A (en) 1997-07-18 2000-01-06 Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor

Country Status (27)

Country Link
EP (1) EP1001784A1 (fr)
JP (1) JP2001510160A (fr)
KR (1) KR20010021952A (fr)
CN (1) CN1263467A (fr)
AP (1) AP2000001735A0 (fr)
AR (2) AR016350A1 (fr)
AU (1) AU8449098A (fr)
BG (1) BG104062A (fr)
BR (1) BR9810292A (fr)
CA (1) CA2297133A1 (fr)
CO (1) CO4940489A1 (fr)
DZ (1) DZ2563A1 (fr)
EA (1) EA200000140A1 (fr)
GB (1) GB9715298D0 (fr)
HU (1) HUP0003626A3 (fr)
ID (1) ID23804A (fr)
IL (1) IL133907A0 (fr)
MA (1) MA24608A1 (fr)
NO (1) NO20000230L (fr)
OA (1) OA11312A (fr)
PE (1) PE99499A1 (fr)
PL (1) PL338140A1 (fr)
SK (1) SK612000A3 (fr)
TR (1) TR200000133T2 (fr)
UY (1) UY25101A1 (fr)
WO (1) WO1999003478A1 (fr)
ZA (1) ZA986364B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
EP1849475A1 (fr) 1999-06-21 2007-10-31 Eli Lilly & Company Utilisation synergique des thiazolidinediones avec peptide-1 comme glucagon et agonistes correspondants pour traiter les diabètes non dépendants de l'insuline
ATE346613T1 (de) * 2000-01-21 2006-12-15 Novartis Pharma Gmbh Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
CA2401356A1 (fr) * 2000-02-24 2001-08-30 Takeda Chemical Industries, Ltd. Medicament combine
US7964216B2 (en) 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
WO2005041962A1 (fr) 2003-10-31 2005-05-12 Takeda Pharmaceutical Company Limited Preparation solide comprenant un sensibilisateur a l'insuline, un secretagogue d'insuline et un ester d'acide gras de polyoxyethylene sorbitan
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993003724A1 (fr) * 1991-08-26 1993-03-04 The Upjohn Company Composition pharmaceutique contenant de l'acide 3-guanidinopropionique ainsi que du glibenclamide ou glimepiride de pioglitazone
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
AR016350A1 (es) 2001-07-04
SK612000A3 (en) 2000-07-11
MA24608A1 (fr) 1999-04-01
CA2297133A1 (fr) 1999-01-28
PL338140A1 (en) 2000-09-25
JP2001510160A (ja) 2001-07-31
BR9810292A (pt) 2000-09-19
UY25101A1 (es) 2000-12-29
PE99499A1 (es) 1999-12-18
CO4940489A1 (es) 2000-07-24
WO1999003478A1 (fr) 1999-01-28
KR20010021952A (ko) 2001-03-15
NO20000230D0 (no) 2000-01-17
GB9715298D0 (en) 1997-09-24
DZ2563A1 (fr) 2003-02-15
ID23804A (id) 2000-05-11
HUP0003626A2 (hu) 2001-05-28
HUP0003626A3 (en) 2001-12-28
CN1263467A (zh) 2000-08-16
ZA986364B (en) 2000-01-17
EP1001784A1 (fr) 2000-05-24
IL133907A0 (en) 2001-04-30
NO20000230L (no) 2000-01-17
EA200000140A1 (ru) 2000-06-26
AR019724A2 (es) 2002-03-13
TR200000133T2 (tr) 2000-09-21
AP2000001735A0 (en) 2000-01-16
AU8449098A (en) 1999-02-10
OA11312A (en) 2003-10-24

Similar Documents

Publication Publication Date Title
BG104060A (en) Diabetes treatment with thiazolyidindion and methformine
AU2373400A (en) Shelf-stable formulation of glucagon-like peptide-1
MXPA02012763A (es) Combinaciones de inhibidores de dipeptidil peptidasa iv y otros agentes antidiabeticos para el tratamiento de diabetes mellitus.
CA2116478A1 (fr) Liberation prolongee de peptides
AU3215597A (en) Method of inhibiting fibrosis with a somatostatin agonist
WO2002048192A3 (fr) Glp-1 amide
BG104135A (en) Diabetes treatment with thiazolydindion, a form increasing the insulin and biguanide secretion
CA2289717A1 (fr) Nouveau traitement de la constipation
IL113566A0 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration
BG104059A (en) Diabetes treatment with rosiglytazone and insulin
BG104062A (en) Treatment of diabetes with thiazolidindion, stimulant of insulin secretion and alpha-glucosidase inhibitor
AU7284098A (en) Method for preventing gastritis using amylin or amylin agonists
BG104139A (en) Diabetes treatment with thizolidindion and sulphonylurea
BG104058A (en) Diabetes treatment with thiazolydindion and sulphonylurea
AU8019898A (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
AP9901720A0 (en) Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitors.
WO1997005875A3 (fr) Procede permettant de reduire la quantite d'insuline exogene administree a un patient souffrant de diabete sucre non-insulinodependant
IL143088A0 (en) A method for the treatment of type 2 diabetes mellitus and conditions associated therewith, and a pharmaceutical composition comprising an insulin sensitiser for use in such a method
YU28700A (sh) Upotreba potencijatora osetljivosti na insulin u proizvodnji leka za lečenje hiperglikemije
MX9709958A (es) Un metodo para reducir la cantidad de insulina exogena administrada a un paciente que tenga diabetes melitus dependiente de insulina.
HUP0000271A2 (en) Use of glucagon-like peptide-1 (glp-1) or analogs to abolish catabolic changes after surgery